Natixis Advisors, L.P. Alnylam Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 10,002 shares of ALNY stock, worth $2.79 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,002Holding current value
$2.79 Million% of portfolio
0.01%Shares
6 transactions
Others Institutions Holding ALNY
# of Institutions
649Shares Held
109MCall Options Held
1.28MPut Options Held
1.22M-
Capital World Investors Los Angeles, CA16.5MShares$4.6 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.52 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.66 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.46 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.38 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $34.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...